Which of Vonoprazan Alone or Intravenous Proton Pump Inhibitor Followed by Vonoprazan Is Optimal for Reducing Delayed Bleeding in Gastric Endoscopic Submucosal Dissection?
Digestion · 2025
DOI: 10.1159/000545253 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Digestion, 2025. Verfasst von Waku Hatta und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Endoscopic Mucosal Resection, Proton Pump Inhibitors, Pyrroles, Sulfonamides. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
In gastric endoscopic submucosal dissection (ESD), both vonoprazan alone and intravenous proton pump inhibitor (PPI) followed by vonoprazan have lower delayed bleeding risk than PPI alone. This study aimed to clarify an optimal acid-suppressive method in gastric ESD.
Methods
This population-based cohort study included patients who underwent gastric ESD on only vonoprazan (vonoprazan alone group) or intravenous PPI followed by vonoprazan (intravenous PPI group) using the Diagnosis Procedure Combination database in Japan between 2014 and 2021. The primary outcome was delayed bleeding. To balance the two comparison groups, propensity score matching (PSM), based on 18 variables, was performed; subsequently, to compare the bleeding outcome, logistic regression analysis was performed.
Results
Of 63,952 patients, 24,710 pairs were compared following PSM. The delayed bleeding risk in the vonoprazan alone group was similar to that in the intravenous PPI group (odds ratio [OR], 1.00; 95% confidence interval, 0.93–1.08; delayed bleeding rate, 5.9% vs. 5.9%). The results were consistent in some sensitivity and subgroup analyses; however, the result was modified by the status of antithrombotic agents (p for interaction = 0.029). In additional analyses, in patients with antithrombotic agent, the vonoprazan alone group had a higher delayed bleeding risk than the intravenous PPI group (OR, 1.15).
Conclusion
Both vonoprazan alone and intravenous PPI followed by vonoprazan might be acceptable in gastric ESD when antithrombotic agents were not administered, whereas intravenous PPI followed by vonoprazan might be favorable in patients with antithrombotic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Health Administration and Policy, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo, Japan.
Zitieren
APA
Hatta, W., Abe, H., Tarasawa, K., Hatta, W., Tanno, N., Hatayama, Y., Ogata, Y., Saito, M., Jin, X., Koike, T., Imatani, A., Hamada, S., Fujimori, K., Fushimi, K., & Masamune, A. (2025). Which of Vonoprazan Alone or Intravenous Proton Pump Inhibitor Followed by Vonoprazan Is Optimal for Reducing Delayed Bleeding in Gastric Endoscopic Submucosal Dissection?. Digestion. https://doi.org/10.1159/000545253
Vancouver
Hatta W, Abe H, Tarasawa K, Hatta W, Tanno N, Hatayama Y, et al. Which of Vonoprazan Alone or Intravenous Proton Pump Inhibitor Followed by Vonoprazan Is Optimal for Reducing Delayed Bleeding in Gastric Endoscopic Submucosal Dissection?. Digestion. 2025. doi:10.1159/000545253
BibTeX
@article{Hatta2025,
author = {Hatta, Waku and Abe, Hiroko and Tarasawa, Kunio and Hatta, Waku and Tanno, Naotaro and Hatayama, Yutaka and Ogata, Yohei and Saito, Masahiro and Jin, Xiaoyi and Koike, Tomoyuki and Imatani, Akira and Hamada, Shin and Fujimori, Kenji and Fushimi, Kiyohide and Masamune, Atsushi},
title = {Which of Vonoprazan Alone or Intravenous Proton Pump Inhibitor Followed by Vonoprazan Is Optimal for Reducing Delayed Bleeding in Gastric Endoscopic Submucosal Dissection?},
journal = {Digestion},
year = {2025},
doi = {10.1159/000545253}
}
EUVIMED